Medicus Pharma wins UAE DOH IND clearance for Teverelix endometriosis Phase 2a trial
MDCX•Study design and endpoint
The placebo-controlled study targets about 84 women across UAE sites.
The primary endpoint is maintaining estradiol in the 20-50 pg/mL range for 14 days.
UAE regulator clears PRECISION-E2 Phase 2a study
Medicus Pharma won UAE Department of Health IND clearance to start the PRECISION-E2 Phase 2a Teverelix study in moderate-to-severe endometriosis.
Regulators completed a review spanning CMC, non-clinical, clinical and safety data; trial start now hinges on site IRB and ethics sign-offs.
